Premium
First Clinical Study of the Selective 5‐HT 3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache
Author(s) -
Couturier E.G.M.,
Hering R.,
Foster C.A.,
Steiner T.J.,
Rose F. Clifford
Publication year - 1991
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.1991.hed3105296.x
Subject(s) - granisetron , migraine , nausea , vomiting , medicine , antagonist , anesthesia , acute migraine , antiemetic , receptor , placebo , alternative medicine , pathology
SYNOPSISGranisetron (BRL 43694), a selective 5‐HT 3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but I patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.